Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Sanofi ( (SNY) ) is now available.
In its Q3 2025 report, Sanofi announced a 7.0% increase in sales at constant exchange rates, driven by strong performances from new pharma launches and Dupixent, despite a decline in vaccine sales. The company achieved significant milestones, including regulatory approvals for Wayrilz and Tzield, and completed the acquisition of Vigil Neuroscience. Sanofi’s strategic focus on science and patient-centric solutions contributed to its continued growth, with plans to complete a €5 billion share buyback by the end of 2025, reinforcing its commitment to delivering shareholder value.
The most recent analyst rating on (SNY) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
Spark’s Take on SNY Stock
According to Spark, TipRanks’ AI Analyst, SNY is a Outperform.
Sanofi’s overall stock score is driven by strong earnings call performance and attractive valuation. Financial stability and solid profitability support the score, despite some challenges in cash flow and revenue growth. Technical analysis indicates a stable market position, contributing to a positive outlook.
To see Spark’s full report on SNY stock, click here.
More about Sanofi
Sanofi is a global healthcare company based in Paris, France, primarily engaged in the pharmaceutical industry. It focuses on developing and marketing a wide range of medicines and vaccines, with significant operations in immunology, rare diseases, and diabetes management.
Average Trading Volume: 3,188,999
Technical Sentiment Signal: Strong Buy
Current Market Cap: $122.7B
Find detailed analytics on SNY stock on TipRanks’ Stock Analysis page.